Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus TELMISARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus TELMISARTAN.
AVALIDE vs TELMISARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Angiotensin II receptor antagonist; selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
40 mg orally once daily; range 20-80 mg/day
None Documented
None Documented
Clinical Note
moderateTelmisartan + Benzydamine
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Benzydamine."
Clinical Note
moderateTelmisartan + Droxicam
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Droxicam."
Clinical Note
moderateTelmisartan + Loxoprofen
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Loxoprofen."
Clinical Note
moderateTelmisartan + Clonixin
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Terminal half-life is approximately 24 hours (range 20–30 hours), supporting once-daily dosing without significant accumulation.
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Primarily biliary-fecal (approximately 97% unchanged in feces); renal excretion accounts for <1% of the dose.
Category C
Category D/X
ARB and Thiazide Diuretic Combination
ARB
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Clonixin."